Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of Sotrovimab IV/IM in Healthy Japanese and Caucasian Participants
NCT04988152Phase 1Completed
- Sponsor
- Vir Biotechnology
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of sotrovimab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Vir Biotechnology. Primary endpoints: Maximum Observed Serum Concentration, Area Under the Serum-concentration Time Curve and 3 more. Started Jul 2021; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04988152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988152.